A citation-based method for searching scientific literature

R B Altman. Clin Pharmacol Ther 2011
Times Cited: 66







List of co-cited articles
589 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity



Pharmacogenetics: from bench to byte--an update of guidelines.
J J Swen, M Nijenhuis, A de Boer, L Grandia, A H Maitland-van der Zee, H Mulder, G A P J M Rongen, R H N van Schaik, T Schalekamp, D J Touw,[...]. Clin Pharmacol Ther 2011
580
33

Clinical implementation of pharmacogenomics: overcoming genetic exceptionalism.
Mary V Relling, Russ B Altman, Matthew P Goetz, William E Evans. Lancet Oncol 2010
72
27

SLCO1B1 variants and statin-induced myopathy--a genomewide study.
E Link, S Parish, J Armitage, L Bowman, S Heath, F Matsuda, I Gut, M Lathrop, R Collins. N Engl J Med 2008
25

HLA-B*5701 screening for hypersensitivity to abacavir.
Simon Mallal, Elizabeth Phillips, Giampiero Carosi, Jean-Michel Molina, Cassy Workman, Janez Tomazic, Eva Jägel-Guedes, Sorin Rugina, Oleg Kozyrev, Juan Flores Cid,[...]. N Engl J Med 2008
25

Adoption of pharmacogenomic testing by US physicians: results of a nationwide survey.
E J Stanek, C L Sanders, K A Johansen Taber, M Khalid, A Patel, R R Verbrugge, B C Agatep, R E Aubert, R S Epstein, F W Frueh. Clin Pharmacol Ther 2012
268
22

The 1200 patients project: creating a new medical model system for clinical implementation of pharmacogenomics.
P H O'Donnell, A Bush, J Spitz, K Danahey, D Saner, S Das, N J Cox, M J Ratain. Clin Pharmacol Ther 2012
119
22

Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing.
M V Relling, E E Gardner, W J Sandborn, K Schmiegelow, C-H Pui, S W Yee, C M Stein, M Carrillo, W E Evans, T E Klein. Clin Pharmacol Ther 2011
358
19

Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.
Jessica L Mega, Tabassome Simon, Jean-Philippe Collet, Jeffrey L Anderson, Elliott M Antman, Kevin Bliden, Christopher P Cannon, Nicolas Danchin, Betti Giusti, Paul Gurbel,[...]. JAMA 2010
725
19

A randomized trial of genotype-guided dosing of warfarin.
Munir Pirmohamed, Girvan Burnside, Niclas Eriksson, Andrea L Jorgensen, Cheng Hock Toh, Toby Nicholson, Patrick Kesteven, Christina Christersson, Bengt Wahlström, Christina Stafberg,[...]. N Engl J Med 2013
541
19

Cytochrome p-450 polymorphisms and response to clopidogrel.
Jessica L Mega, Sandra L Close, Stephen D Wiviott, Lei Shen, Richard D Hockett, John T Brandt, Joseph R Walker, Elliott M Antman, William Macias, Eugene Braunwald,[...]. N Engl J Med 2009
18

Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing.
J A Johnson, L Gong, M Whirl-Carrillo, B F Gage, S A Scott, C M Stein, J L Anderson, S E Kimmel, M T M Lee, M Pirmohamed,[...]. Clin Pharmacol Ther 2011
423
18

Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype.
K R Crews, A Gaedigk, H M Dunnenberger, T E Klein, D D Shen, J T Callaghan, E D Kharasch, T C Skaar. Clin Pharmacol Ther 2012
252
18

Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy.
Alan R Shuldiner, Jeffrey R O'Connell, Kevin P Bliden, Amish Gandhi, Kathleen Ryan, Richard B Horenstein, Coleen M Damcott, Ruth Pakyz, Udaya S Tantry, Quince Gibson,[...]. JAMA 2009
18

The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Initiative: methods of the EGAPP Working Group.
Steven M Teutsch, Linda A Bradley, Glenn E Palomaki, James E Haddow, Margaret Piper, Ned Calonge, W David Dotson, Michael P Douglas, Alfred O Berg. Genet Med 2009
464
16

Pharmacogenetics: from bench to byte.
J J Swen, I Wilting, A L de Goede, L Grandia, H Mulder, D J Touw, A de Boer, J M H Conemans, T C G Egberts, O H Klungel,[...]. Clin Pharmacol Ther 2008
149
16

Pharmacogenetic tests: the need for a level playing field.
Munir Pirmohamed, Dyfrig A Hughes. Nat Rev Drug Discov 2013
26
42

Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update.
S A Scott, K Sangkuhl, C M Stein, J-S Hulot, J L Mega, D M Roden, T E Klein, M S Sabatine, J A Johnson, A R Shuldiner. Clin Pharmacol Ther 2013
546
16

Pharmacogenomics in the clinic.
Mary V Relling, William E Evans. Nature 2015
364
16

Preemptive clinical pharmacogenetics implementation: current programs in five US medical centers.
Henry M Dunnenberger, Kristine R Crews, James M Hoffman, Kelly E Caudle, Ulrich Broeckel, Scott C Howard, Robert J Hunkler, Teri E Klein, William E Evans, Mary V Relling. Annu Rev Pharmacol Toxicol 2015
259
16

Estimation of the warfarin dose with clinical and pharmacogenetic data.
T E Klein, R B Altman, N Eriksson, B F Gage, S E Kimmel, M-T M Lee, N A Limdi, D Page, D M Roden, M J Wagner,[...]. N Engl J Med 2009
15

The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy.
R A Wilke, L B Ramsey, S G Johnson, W D Maxwell, H L McLeod, D Voora, R M Krauss, D M Roden, Q Feng, R M Cooper-Dehoff,[...]. Clin Pharmacol Ther 2012
217
15

Operational implementation of prospective genotyping for personalized medicine: the design of the Vanderbilt PREDICT project.
J M Pulley, J C Denny, J F Peterson, G R Bernard, C L Vnencak-Jones, A H Ramirez, J T Delaney, E Bowton, K Brothers, K Johnson,[...]. Clin Pharmacol Ther 2012
269
15

Adoption of a clinical pharmacogenomics implementation program during outpatient care--initial results of the University of Chicago "1,200 Patients Project".
Peter H O'Donnell, Keith Danahey, Michael Jacobs, Nisha R Wadhwa, Shennin Yuen, Angela Bush, Yasmin Sacro, Matthew J Sorrentino, Mark Siegler, William Harper,[...]. Am J Med Genet C Semin Med Genet 2014
79
15


Clinical assessment incorporating a personal genome.
Euan A Ashley, Atul J Butte, Matthew T Wheeler, Rong Chen, Teri E Klein, Frederick E Dewey, Joel T Dudley, Kelly E Ormond, Aleksandra Pavlovic, Alexander A Morgan,[...]. Lancet 2010
464
13

A pharmacogenetic versus a clinical algorithm for warfarin dosing.
Stephen E Kimmel, Benjamin French, Scott E Kasner, Julie A Johnson, Jeffrey L Anderson, Brian F Gage, Yves D Rosenberg, Charles S Eby, Rosemary A Madigan, Robert B McBane,[...]. N Engl J Med 2013
501
13

The Pharmacogenomics Research Network Translational Pharmacogenetics Program: overcoming challenges of real-world implementation.
A R Shuldiner, M V Relling, J F Peterson, J K Hicks, R R Freimuth, W Sadee, N L Pereira, D M Roden, J A Johnson, T E Klein,[...]. Clin Pharmacol Ther 2013
115
13

Genomics and drug response.
Liewei Wang, Howard L McLeod, Richard M Weinshilboum. N Engl J Med 2011
374
12

Development and implementation of a pharmacist-managed clinical pharmacogenetics service.
Kristine R Crews, Shane J Cross, John N McCormick, Donald K Baker, Alejandro R Molinelli, Richard Mullins, Mary V Relling, James M Hoffman. Am J Health Syst Pharm 2011
101
12

Clinically actionable genotypes among 10,000 patients with preemptive pharmacogenomic testing.
S L Van Driest, Y Shi, E A Bowton, J S Schildcrout, J F Peterson, J Pulley, J C Denny, D M Roden. Clin Pharmacol Ther 2014
167
12

PG4KDS: a model for the clinical implementation of pre-emptive pharmacogenetics.
James M Hoffman, Cyrine E Haidar, Mark R Wilkinson, Kristine R Crews, Donald K Baker, Nancy M Kornegay, Wenjian Yang, Ching-Hon Pui, Ulrike M Reiss, Aditya H Gaur,[...]. Am J Med Genet C Semin Med Genet 2014
150
12

Pharmacogenomics knowledge for personalized medicine.
M Whirl-Carrillo, E M McDonagh, J M Hebert, L Gong, K Sangkuhl, C F Thorn, R B Altman, T E Klein. Clin Pharmacol Ther 2012
922
12

Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy.
S A Scott, K Sangkuhl, E E Gardner, C M Stein, J-S Hulot, J A Johnson, D M Roden, T E Klein, A R Shuldiner. Clin Pharmacol Ther 2011
308
10

Is there a need for PGxceptionalism?
Muin J Khoury, Marta Gwinn, W David Dotson, M Scott Bowen. Genet Med 2011
8
87

A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose.
Gregory M Cooper, Julie A Johnson, Taimour Y Langaee, Hua Feng, Ian B Stanaway, Ute I Schwarz, Marylyn D Ritchie, C Michael Stein, Dan M Roden, Joshua D Smith,[...]. Blood 2008
311
10

A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose.
Fumihiko Takeuchi, Ralph McGinnis, Stephane Bourgeois, Chris Barnes, Niclas Eriksson, Nicole Soranzo, Pamela Whittaker, Venkatesh Ranganath, Vasudev Kumanduri, William McLaren,[...]. PLoS Genet 2009
448
10

Genetic determinants of response to clopidogrel and cardiovascular events.
Tabassome Simon, Céline Verstuyft, Murielle Mary-Krause, Lina Quteineh, Elodie Drouet, Nicolas Méneveau, P Gabriel Steg, Jean Ferrières, Nicolas Danchin, Laurent Becquemont. N Engl J Med 2009
10

Effects of CYP2C19 genotype on outcomes of clopidogrel treatment.
Guillaume Paré, Shamir R Mehta, Salim Yusuf, Sonia S Anand, Stuart J Connolly, Jack Hirsh, Katy Simonsen, Deepak L Bhatt, Keith A A Fox, John W Eikelboom. N Engl J Med 2010
390
10

Implementing personalized medicine: development of a cost-effective customized pharmacogenetics genotyping array.
J A Johnson, B M Burkley, T Y Langaee, M J Clare-Salzler, T E Klein, R B Altman. Clin Pharmacol Ther 2012
74
10

The CLIPMERGE PGx Program: clinical implementation of personalized medicine through electronic health records and genomics-pharmacogenomics.
O Gottesman, S A Scott, S B Ellis, C L Overby, A Ludtke, J-S Hulot, J Hall, K Chatani, K Myers, J L Kannry,[...]. Clin Pharmacol Ther 2013
97
10

Design and anticipated outcomes of the eMERGE-PGx project: a multicenter pilot for preemptive pharmacogenomics in electronic health record systems.
L J Rasmussen-Torvik, S C Stallings, A S Gordon, B Almoguera, M A Basford, S J Bielinski, A Brautbar, M H Brilliant, D S Carrell, J J Connolly,[...]. Clin Pharmacol Ther 2014
145
10

HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin.
Ann K Daly, Peter T Donaldson, Pallav Bhatnagar, Yufeng Shen, Itsik Pe'er, Aris Floratos, Mark J Daly, David B Goldstein, Sally John, Matthew R Nelson,[...]. Nat Genet 2009
648
9

HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans.
Mark McCormack, Ana Alfirevic, Stephane Bourgeois, John J Farrell, Dalia Kasperavičiūtė, Mary Carrington, Graeme J Sills, Tony Marson, Xiaoming Jia, Paul I W de Bakker,[...]. N Engl J Med 2011
573
9


Clinical application of pharmacogenetics.
B B Spear, M Heath-Chiozzi, J Huff. Trends Mol Med 2001
293
9

The path to personalized medicine.
Margaret A Hamburg, Francis S Collins. N Engl J Med 2010
954
9

CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial.
Meredith M Regan, Brian Leyland-Jones, Mark Bouzyk, Olivia Pagani, Weining Tang, Roswitha Kammler, Patrizia Dell'orto, Maria Olivia Biasi, Beat Thürlimann, Maria B Lyng,[...]. J Natl Cancer Inst 2012
232
9

Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2.
Simone Rost, Andreas Fregin, Vytautas Ivaskevicius, Ernst Conzelmann, Konstanze Hörtnagel, Hans-Joachim Pelz, Knut Lappegard, Erhard Seifried, Inge Scharrer, Edward G D Tuddenham,[...]. Nature 2004
781
9



Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.